发明名称 Prostate cancer biomarkers
摘要 The present disclosure relates to a method of determining whether a mammalian subject belongs to a first or a second group of subjects, wherein the risk of having a prostate cancer, such as an aggressive prostate cancer, is higher in the first group than in the second group. The method comprises the steps of: a) evaluating an amount of unglycosylated CNDP1 protein in a sample derived from blood, semen or urine from the subject and determining a sample value corresponding to the evaluated amount; b) comparing the sample value with a predetermined reference value; and if the sample value is lower than or equal to the reference value, c1) concluding that the subject belongs to the first group; and if the sample value is higher than the reference value, c2) concluding that the subject belongs to the second group. Further, the present disclosure relates to a similar method based on the protein HCRTR1 as well as corresponding uses and means useful when carrying out the methods.
申请公布号 EP2390665(A1) 申请公布日期 2011.11.30
申请号 EP20100164107 申请日期 2010.05.27
申请人 ATLAS ANTIBODIES AB 发明人 UHLEN, MATHIAS;SCHWENK, JOCHEN;NILSSON, PETER
分类号 G01N33/574;C07K16/40 主分类号 G01N33/574
代理机构 代理人
主权项
地址
您可能感兴趣的专利